1. Loorand-Stiver L. Drugs for rare diseases: evolving trends in regulatory and health technology assessment perspectives [environmental scan, issue 42]. Ottawa: Canadian Agency for Drugs and Technologies in. Health; 2013.
http://www.cadth.ca/media/pdf/ES0281_RareDiseaseDrugs_es_e.pdf
. Accessed 20 Dec 2017
2. BIOTECanada. The Canadian rare disease therapies landscape: Bridging opportunity to reality.
http://www.biotech.ca/wp-content/uploads/2016/03/white_paper_mar_2.pdf
. Accessed 20 Dec 2017.
3. Canadian Institute of Health Research. New emerging team for rare diseases.
http://rare-diseases.ca/
. Accessed 20 Dec 2017.
4. Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM. 2005;98:829–36.
5. Drummond MF, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23:36–42.